The world is six months into the COVID-19 pandemic, the global response to which is unprecedented in human history. But just as the pandemic has tightened borders, closed workplaces, and isolated people in their homes, scientific borders have been flung open and barriers torn down. Despite academic institutes and laboratories being shuttered worldwide, the urgency and pace of the pandemic has spawned a new era of scientific collaboration, open discourse, and efficiency. These collaborative efforts have included substantial input from rheumatologists---an eventuality that was mostly unanticipated in the early months of 2020.

Since the first reports of disease caused by the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) in December 2019, hundreds of clinical trials have been designed, launched, and completed enrolment at an extraordinary pace, thanks in part to concerted global and national efforts to fast-track COVID-19 research. These efforts include WHO\'s global initiative [Access to COVID-19 Tools (ACT) Accelerator](https://www.who.int/who-documents-detail/access-to-covid-19-tools-(act)-accelerator){#interrefs10}, which aims to rapidly develop and ensure equitable global access to diagnostics, therapeutics, and vaccines, and the UK\'s [ACCORD (Accelerating, COVID-19 Research & Development)](https://www.nihr.ac.uk/news/national-collaborative-platform-launched-to-fast-track-potential-covid-19-treatments/24678){#interrefs20} platform, aiming to identify promising therapies for COVID-19 and rapidly advance them into clinical trials.

Rheumatologists have a prominent role in these clinical trials; many are also treating patients with severe COVID-19 on the 'front lines.' These patients can develop a hyperinflammatory condition called cytokine storm, in which over-exuberant production of cytokines contributes to development of acute respiratory distress syndrome (ARDS), multiorgan failure, and often death. Rheumatologists\' are experienced in managing cytokine storm syndromes in the context of their own patients---such as those with systemic juvenile idiopathic arthritis, Still\'s disease, and lupus---and in use of the therapies to blunt cytokine overproduction (eg, the interleukin \[IL\]-1 receptor antagonist anakinra, the IL-6 receptor inhibitor tocilizumab).

In an auspiciously-timed [Viewpoint](https://doi.org/10.1016/S2665-9913(20)30096-5){#interrefs30} (commissioned before the onset of COVID-19) in *The Lancet Rheumatology*, Puja Mehta and colleagues outline the rationale for and safety of high-dose, intravenous anakinra in patients with secondary haemophagocytic lymphohistiocytosis (HLH), a type of cytokine storm syndrome that can develop in response to infection, malignancy, or autoimmune diseases, including rheumatic diseases. The commonalities between HLH and severe COVID-19, have informed treatment of patients with COVID-19 and ongoing trials. Indeed, preliminary data from a [retrospective series](https://doi.org/10.1016/S2665-9913(20)30127-2){#interrefs40} of 29 Italian patients with severe COVID-19 and evidence of hyperinflammation suggest that intravenous anakinra could be beneficial in these patients, although conclusive evidence awaits results of ongoing randomised trials.

In many ways, SARS-CoV-2 has been a great unifier. The rapid gains in our understanding of the virus and the disease it causes have drawn on the expertise of clinicians and scientists across specialties. Epidemiologists, virologists and infectious disease specialists are discovering aspects of viral tropism, mutation, and transmission; critical care and respiratory medicine specialists are managing ARDS and multiorgan failure in severe cases; haematologists and pathologists are revealing the mechanisms and characteristics of pulmonary thrombosis and coagulopathy often seen in the disease; and rheumatologists are helping to decipher the mechanisms of and treatments for cytokine storm.

The power of such cross-specialty collaboration to produce insights into a complex disease, with the urgency and pace demanded by a global pandemic, has prompted us to reflect on the original scope of *The Lancet Rheumatology*, much as the pandemic itself has prompted many people to reflect on fundamental aspects of their lives and livelihoods. As such, it seems timely to reemphasise our interest in diseases and conditions that perhaps fall outside---or along the margins---of traditional rheumatology and musculoskeletal diseases. While our primary focus will remain on these diseases, we continue to welcome original research, clinical trials, and translational studies that illuminate the biology, predictors, and treatment of immune system diseases and cytokine-opathies. In short, we are keen to see submissions from research areas in which traditional rheumatic and musculoskeletal diseases might overlap with and reciprocally inform other conditions, as has been so powerfully demonstrated for COVID-19.

The COVID-19 pandemic will eventually fade, but we hope that the transformation of science it has stimulated will be embraced, celebrated, and cultivated long afterwards.
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